Background: Recently, 44 Sc (T 1/2 = 3.97 h, Eβ
Background 44 Sc is a novel radiometal which is attractive for positron emission tomography (PET) imaging, due to the emission of positrons with a high branching ratio (Eβ + av = 632 keV, I = 94.3 %) (Rösch 2012; Müller et al. 2013) . Its physical half-life of 3.97 h enables the acquisition of PET images several hours after injection of the 44 Sc-radiopharmaceutical and is of particular interest for application with biomolecules, providing slower kinetic profiles (Chakravarty et al. 2014) . Importantly, application of 44 Sc would allow a centralized production of radiopharmaceuticals, followed by transportation to more remote hospitals (van der Meulen et al. 2015) . 44 Sc is thought to be useful as a diagnostic match to therapeutic radionuclides with similar chemical properties, such as 90 Y and 177 Lu (Müller et al. 2013 ). Most interesting, however, would be to use 44 Sc in combination with its therapeutic counterpart 47 Sc, which provides excellent β − -decay properties for radionuclide therapy (Eβ − av = 162 keV, T 1/2 = 3.35 d). The potential of 44 Sc/ 47 Sc as a theragnostic pair has been demonstrated recently in a preclinical pilot study with tumor-bearing mice (Müller et al. 2014) . A crucial requirement for the application of radiopharmaceuticals is the formation of a thermodynamically stable and kinetically inert complex of the radiometal with a suitable chelator, which is then linked to the targeting agent (Majkowska-Pilip & Bilewicz 2011) . The coordination of Sc(III) and Ga(III) has previously been investigated with several macrocyclic polyaminocarboxylic chelators, including 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) (Majkowska-Pilip & Bilewicz 2011; Huclier-Markai et al. 2011; Notni et al. 2012) . The studies were performed with nat Sc(III) stock solutions containing 46 Sc as tracer and the sole chelator without an attached biomolecule. As a result of these investigations, it was found that Sc(III) forms complexes with both chelators, DOTA and NOTA, however, the stability of Sc-DOTA was superior to Sc-NOTA complexes (Majkowska-Pilip & Bilewicz 2011; Huclier-Markai et al. 2011) . On the other hand, Ga(III) displays a reverse behavior, forming more stable complexes with NOTA than with DOTA (Majkowska-Pilip & Bilewicz 2011; Notni et al. 2012) . The DOTA-chelator provides eight coordination sites, which are all coordinated by Sc(III), whereas NOTA can only form six coordinative bonds. Due to the higher denticity the Sc-DOTA complex is believed to be thermodynamically more stable than the Sc-NOTA complex (Huclier-Markai et al. 2011; Port et al. 2008) . Due to the preference of Ga(III) for the coordination number six, all coordination sites of NOTA are used, while two sites of DOTA remain uncoordinated in a Ga-DOTA-complex (Majkowska-Pilip & Bilewicz 2011; Viola-Villegas & Doyle 2009) .
Despite the reduced stability of a Ga-DOTA complex compared to a Ga-NOTA and Ga-1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) complex, there are several examples of 68 Ga-DOTA labeled peptides which showed promising in vivo properties . The   68   Ga-labeled somatostatin receptor analogues   68   Ga-DOTA-TOC,   68   Ga-DOTA-TATE and   68 Ga-DOTA-NOC represent the most prominently applied radiopharmaceuticals in clinical studies for imaging of neuroendocrine tumors (Kwekkeboom et al. 2010) . Recent PET imaging studies in patients using the α v β 3 integrin-targeting radiotracer 68 Ga-NOTA-RGD indicated promising results (Kim et al. 2012; Choi et al. 2013; Yoon et al. 2014 ). These reports demonstrate that 68 Ga is successfully used in clinics with both DOTA-and NOTA/NODAGA-derivatized targeting agents.
The stable complexation of 44 Sc with DOTA initiated a number of preclinical studies with a range of DOTA-derivatized biomolecules, including bombesin analogues (Koumarianou et al. 2012) , puromycin (Eigner et al. 2013) , folate-conjugates (Müller et al. 2013 ) and dimeric cyclic RGD peptides (Hernandez et al. 2014) . To date, all research with regard to the in vivo and in vitro behavior of 44 Sc-labeled radiopharmaceuticals was performed with DOTA chelators connected to the respective targeting agent. The only exception to our knowledge was a study in which an EGFR-targeted antibody was labeled with 44 Sc using a CHX-A-DTPA (N-[(R)-2-amino-3-(para-isothiocyanato-phenyl)propyl]trans-(S,S)-cyclohexane-1,2-diamine N,N,N' ,N"N"-pentaacetic acid) chelator (Chakravarty et al. 2014) . The question on whether or not a NOTA or NODAGA chelator would be suited for 44 Sc-labeling has remained unclear thus far. Using these chelators for coordination of 44 Sc would be of interest in combination with radiopharmaceuticals where only the NOTA-or NODAGA-derivatized species are available for clinical studies, as is the case for NODAGA-RGD: a peptide which is currently employed in clinical trials when labeled with 68 Ga. Since application of NODAGA-RGD at later time points after injection of the radioconjugate would be of interest for nuclear physicians, we set out to investigate whether 44 Sc-labeling with NODAGA-derivatized biomolecules is possible and whether the in vitro and in vivo behavior of the radiolabeled peptides would be equal to the DOTA-derivatized matches.
The aim of this study was, therefore, to compare the in vitro and in vivo behavior of two pairs of peptides with a DOTA-and NODAGA-chelator ( Fig. 1) Ca targets at the Injector 2 cyclotron at PSI, as previously reported (van der Meulen et al. 2015) . The irradiation of targets with 11 MeV proton beam energy, and a beam current of 50 μA, lasted for 90 min. A column (1 mL cartridge fitted with 20 μm frit ISOLUTE SPE Accessories, UK) was filled with 50 -70 mg DGA extraction chromatographic resin and a second column with 20-25 mg of the same resin. A 20 μm frit was placed on top of the resin in each column. DGA columns were preconditioned with 3.0 M HCl. The first step of the separation was performed as previously reported (van der Meulen et al. 2015) . In brief, the target was dissolved in 2.5 mL 3.0 M HCl and loaded onto the first DGA column. The rinsing of the target container and the first DGA column with 3.0 M HCl ensured a complete transfer of the 44 Sc radioactivity and complete removal of residual Ca(II), respectively. 44 Sc was eluted from the first DGA column with 3.5 mL 0.1 M HCl. Subsequently, the solution was acidified with the addition of 3.3 mL 6.0 M HCl to yield a 3.0 M HCl solution, which was then passed through the second DGA column, to which the 44 Sc activity was sorbed. The elution of 44 Sc from the second column was performed with 700 μL 0.05 M HCl (pH 1.3) and was used directly for labeling reactions. The radionuclidic purity of the 44 Sc-eluate was quantified by γ-spectrometry using an N-type high-purity germanium (HPGe) coaxial detector (EURISYS MESURES, France) and the Ortec InterWinner 7.1 software. The 44 Ca-contained waste fraction from the first DGA column was collected and processed to recover the target material, as described previously (van der Meulen et al. 2015) .
Radiolabeling of DOTA-and NODAGA-functionalized peptides
The total 44 Sc and 68 Ga activity in the obtained eluate was quantitatively determined with a dose calibrator (ISOMED 2010, Nuclear-Medizintechnik Dresden GmbH, Germany) so that the activity required for radiolabeling could be withdrawn. Sodium acetate solution (0.5 M, pH 8) was added at a ratio of 1:1 to the 44 Sc eluate (0.05 M HCl, pH 0.4-0.6) and at a ratio of 1:2 to the 68 Ga generator eluate (0.1 M HCl, pH 1)
to give a pH of 4-4.5. The corresponding peptides (DOTA-RGD, NODAGA-RGD, DOTA-NOC and NODAGA-NOC, in a 1 mM stock solution) were added to obtain a specific activity of up to 10 MBq/nmol and the reaction mixture incubated at 95°C for 10 min. High-performance liquid chromatography (HPLC) with a C-18 reversed-phase column (Xterra TM MS, C18, 5 μm, 150 × 4.6 mm; Waters) was used for quality control.
The mobile phase consisted of MilliQ water containing 0.1 % trifluoracetic acid (A) and acetonitrile (B) with a gradient of 95 % A and 5 % B to 20 % A and 80 % B over a period of 15 min at a flow rate of 1.0 mL/min.
In vitro stability of 44 Ga-labeled peptides 44 Sc-and 68 Ga-labeled peptides (radiochemical purity >95 %) were used for the investigation of stability in 0.9 % NaCl. An activity of 80-100 MBq of 44 Sc or 68 Ga labeling solution was diluted with 0.9 % NaCl solution to a volume of 800 μL and incubated for four half-lives of the corresponding radionuclide at 37°C. Aliquots were taken from the prepared solutions at different time points over at least four half-lives, respectively, of 44 Sc and 68 Ga and analyzed by TLC (TLC was used, as the high metal concentrations used in this study may impair the long-term performance of HPLC columns). If initial experiments suggested instability of a compound, aliquots were retrieved more frequently. The TLC plates (Silica-gel 60, Merck) were developed using 0.1 M sodium citrate (pH 4.7) as mobile phase. The quantitative distribution of radioactivity was determined with an autoradiography system (Cyclone Plus, Perkin Elmer) and its associated software (Optiquant, version 5.0). R f values of 0.2 were observed for 44 Ga-labeled DOTA-RGD and NODAGA-RGD, and of 0.1 for DOTA-NOC and NODAGA-NOC, respectively, whereas for unlabeled 44 Sc and 68 Ga a R f value of 0.9 was calculated.
The influence of high metal cation concentration on the stability of 44 ) and AR42J cells (rat exocrine pancreatic tumor cells; ACC® CRL1492 TM ) were purchased from European Collection of Cell Cultures (ECACC, operated by Public Health England). U87MG cells were grown in MEM cell culture medium supplemented with 1 % non-essential amino acids (MEM NEAA solution 100×, Bioconcept), 1 mM sodium pyruvate (Bioconcept), 10 % fetal calf serum, L-glutamine and antibiotics. AR42J cells were grown in RPMI cell culture medium supplemented with 10 % fetal calf serum, L-glutamine and antibiotics. Routine cell culture was performed twice a week using trypsin (Gibco by life technologies 0.25 % trypsin-EDTA) for detachment of the cells.
Tumor mouse models
In vivo experiments were approved by the local veterinarian department and conducted in accordance with the Swiss law of animal protection. Female athymic nude mice (CD-1 nude), age 5-6 weeks, were obtained from Charles River Laboratories, Sulzfeld, Germany. U87MG cells and AR42J-cells were suspended in PBS (5 × 10 6 cells in 100 μL) and subcutaneously inoculated on each shoulder. Two to three weeks later, when the tumor reached a size of about 300-500 mm 3 , the mice were used for the in vivo studies.
Biodistribution studies
Biodistribution studies were performed with U87MG tumor and AR42J tumor-bearing mice 2 weeks after tumor cell inoculation. 44 Sc-and 68 Ga-labeled peptides (~5 MBq, 1 nmol per mouse) were intravenously injected in a volume of 100-200 μL. Mice were sacrificed at 30 min, 2 h and 5 h after injection (p.i.) of the 44 Sc-labeled peptides. Mice which were injected with 68 Ga-labeled peptides were sacrificed at 30 min and 2 h p.i.
Selected tissues and organs were collected, weighed, and counted for radioactivity using a γ-counter (Wallac Wizard 1480, Perkin Elmer). The results were listed as a percentage of the injected activity per gram of tissue mass (% IA/g), using counts of a defined volume of the original injection solution counted at the same time. The data were analyzed for significance using a two-way ANOVA test (Graph Pad Prism 6 software, version 6.05). A p-value of < 0.05 was considered statistically significant.
Preclinical PET imaging
A bench-top preclinical PET scanner (G8, Sofie Biosciences, California, U.S.A. and Perkin Elmer, Massachusetts, U.S.A.) was employed for the PET scans of the tumor-bearing mice. The energy window was set to 150-650 keV. Mice were injected intravenously with 44 Sc-or 68 Ga-labeled peptides (~10 MBq,~1 nmol per mouse) in a volume of 100-200 μL. The PET scans were performed 3 h and 5 h after injection of the 44 Sc-labeled peptides and 3 h after injection of the 68 Ga-labeled peptides, using G8 acquisition software (version 2.0.0.10). All static PET scans lasted for 20 min. During the acquisition the mice were anesthetized by inhalation of a mixture of isoflurane and oxygen. The images were reconstructed with maximum-likelihood expectation maximization (MLEM). Gauss postreconstruction filtering was performed using VivoQuant post-processing software (version 2.10, inviCRO Imaging Services and Software, Boston, U.S.A.).
Results
Production and separation of 44 Sc 44 Sc was quantitatively sorbed on DGA resin in 3.0 M HCl solution, whereas Ca was not retained. Rinsing the resin with additional 4 mL 3.0 M HCl ensured the complete removal of Ca, after which 44 Sc was eluted with 3.5 mL 0. was also possible at room temperature in less than 10 min. TLC and HPLC quality control were in good agreement. HPLC analysis demonstrated a peak of free 44 Sc and 68 Ga at a retention time of 2.2 ± 0.1 min, while the retention times of the radiopeptides were between 6 and 10 min ( Table 1) . The stability of 44 Sc-and 68 Ga-labeled DOTA-and NODAGA-peptides was first investigated in 0.9 % NaCl over a period of four half-lives of the corresponding nuclide by means of TLC. 44 Sc-and 68 Ga-DOTA-RGD and DOTA-NOC exhibited a high stability. After four half-lives at 37°C the amount of intact compound did not decrease below 98 %. 68 Ga-labeled NODAGA-RGD and NODAGA-NOC remained stable, but the 44 Sc-NODAGA peptides became more unstable over time. The amount of intact 44 Sc-NODAGA-RGD dropped to 77 % and, in the case of 44 Sc-NODAGA-NOC, a mere 37 % after more than 4 half-lives. The presence of different metal cations can cause displacement of the radionuclide from the chelator and its release into solution (Pruszynski et al, 2012) . The stability of 44 Sc-and 68 Ga-labeled DOTA-and NODAGA-peptides was investigated in the presence of Fe 3+ and Cu 2+ over four half-lives of the corresponding radionuclide (Fig. 2) . The addition of solutions containing these metal cations to result in final metal concentrations as high as 10 mM did not induce any transmetalation of 44 Sc-labeled DOTA-and 68 Ga-labeled NODAGA-compounds. The integrity of 68 Ga-DOTA-peptides was not impaired by the presence of Fe 3+ , however, the addition of 10 mM Cu 2+ reduced the amount of intact 68 Ga-DOTA-RGD to 10 % Ga-DOTA-RGD (c), 68 Ga-NODAGA-RGD (d), 44 Sc-DOTA-NOC (e), 44 Sc-NODAGA-NOC (f), 68 Ga-DOTA-NOC (g), 68 Ga-NODAGA-NOC (h) in saline with and without the presence of 10 mM Cu 2+ and Fe
3+
, respectively Ga-labeled DOTA/NODAGA-RGD and DOTA/NODAGA-NOC in mice bearing U87MG and AR42J tumor xenografts, respectively (Additional file 1: Table S2-S5).
Time-dependent distribution studies of 44 Sc-DOTA-RGD and 44 Sc-NODAGA-RGD revealed a similar pattern for both compounds, resulting in a tumor uptake of 4.88 ± 0.67 % IA/g and 4.50 ± 0.77 % IA/g, respectively, at 0.5 h after injection (Fig. 3a) . The wash-out of radioactivity from the tumor tissue was somewhat faster for the 44 Sc-DOTA-RGD than for the 44 Sc-NODAGA-RGD, but at 5 h after injection the values were almost the same (3.00 ± 0.38 % IA/g vs 3.01 ± 0.55 % IA/g). Clearance from the blood was fast for both 44 Sc-DOTA-RGD and 44 Sc-NODAGA-RGD. This was also reflected by the high renal uptake shortly after injection (4.44 ± 0.51 % IA/g vs 3.89 ± 0.68 % IA/g, 0.5 h p.i.) which decreased with time, resulting in a retention of <2 % IA/g at 5 h p.i. Whereas the accumulation in non-targeted organs and tissues was generally comparable, the liver uptake of 44 Sc-DOTA-RGD (5.16 ± 0.99 % IA/g, 0.5 h) was clearly higher than for 44 Sc-NODAGA-RGD (1.49 ± 0.06 % IA/g, 0.5 h) at early time points. At 5 h after injection uptake in the liver was~1 % IA/g for both radiopeptides (Fig. 3a) .
The tissue distribution pattern of 44 Sc-DOTA-NOC and 44 Sc-NODAGA-NOC was comparable with regard to the uptake in AR42J tumors (9.49 ± 0.76 % IA/g vs. 9.90 ± 0.66 % IA/g), kidneys (12.6 ± 3.36 % IA/g vs. 12.4 ± 1.41 % IA/g) and liver (1.49 ± 0.49 % IA/g vs. 1.22 ± 0.11 % IA/g) at 0.5 h after injection (Fig. 3b) . The tissue distribution profiles at 2 h after injection of the NOC-based radiopeptides were also comparable. At 5 h after injection, retention of 44 Sc-DOTA-NOC in tumors (5.56 ± 0.40 % IA/g) was lower than for 44 Sc-NODAGA-NOC (10.8 ± 0.37 % IA/g), which indicates a faster wash-out of 44 Sc-DOTA-NOC. Renal retention of 44 Sc-DOTA-NOC decreased further over the period of investigation (6.54 ± 0.30 % IA/g, 5 h p.i.) while the accumulation of activity in the kidneys (13.0 ± 2.98 % IA/g) was increased at 5 h after injection of 44 Sc-NODAGA-NOC (Fig. 3b) .
For selected organs and tissues, the uptake of the 44 Sc-labeled peptides was compared with the uptake of the 68 Ga-labeled peptides in mice at 2 h after injection (Fig. 4) . The tissue distribution of DOTA-RGD was almost the same, independent of the radionuclide ( 44 Sc vs 68 Ga) used (Fig. 4a) , although the tumor uptake was higher for 44 Sc-DOTA-RGD (2.99 ± 0.16 % IA/g) than for 68 Ga-DOTA-RGD (2.35 ± 0.27 % IA/g, p <0.05). The NODAGA-derivatized RGD-peptides revealed the same trend: the tumor uptake of 44 Sc-NODAGA-RGD (4.05 ± 0.89 IA/g) was significantly higher (p <0.05) than the tumor uptake of 68 Ga-NODAGA-RGD (3.13 ± 0.27 % IA/g). Undesired accumulation of 44 Sc-NODAGA-RGD in the liver (1.34 ± 0.27 % IA/g, p <0.05) was significantly reduced compared to 68 Ga-NODAGA-RGD (2.09 ± 0.08 % IA/g, Fig. 4b ). Renal uptake of 44 Sc-NODAGA-RGD was also slightly lower than for 68 Ga-NODAGA-RGD. The DOTA-RGD accumulated to a higher extent in the liver than the NODAGA-RGD, irrespective of which radionuclide was used for labeling ( Fig. 4a/b) . In all other organs of interest, the distribution profile was roughly the same, irrespective of the chelator used for coordination of the radionuclide.
Accumulation of 44 Sc-DOTA-NOC in the tumor xenografts (8.83 ± 0.57 % IA/g) was significantly lower (p <0.05) when compared to the uptake of 68 Ga-DOTA-NOC (12.2 ± 2.29 % IA/g) (Fig. 4c) . This was also the case in the liver, where the uptake of NOC (0.68 ± 0.07 % IA/g) was significantly (p <0.05) lower than for 68 Ga-DOTA-NOC (5.52 ± 0.88 % IA/g). In all other organs and tissues the distribution of radioactivity was comparable among the radiopeptides, irrespective of whether they were labeled with 44 Sc or 68 Ga (Fig. 4c) . The tissue distribution of 44 Sc-NODAGA-NOC and 68 Ga-NODAGA-NOC was also comparable (Fig. 4d) . The only significant difference (p <0.05) were the kidneys, in which 44 Sc-NODAGA-NOC was less retained (8.64 ± 1.62 % IA/g) than the 68 Ga-NODAGA-NOC (11.5 ± 1.15 % IA/g). The liver uptake of 44 Sc-NODAGA-NOC (0.88 ± 0.15 % IA/g) was lower than for 68 Ga-NODAGA-NOC (1.68 ± 0.19 % IA/g) but the difference was not significant (Fig. 4c) . Comparison of the DOTA-NOC and NODAGA-NOC revealed similar distribution profiles, irrespective of the radionuclide employed. As the only exception, it should be mentioned that 68 Ga-DOTA-NOC showed a clearly higher retention in the liver than all other NOC-based radiopeptides (Fig. 4c/d) .
As a result of the tissue distribution data reported above, the tumor-to-background ratios were mostly similar between 44 Sc-labeled DOTA-RGD and NODAGA-RGD as Sc-DOTA/NODAGA-RGD in U87MG tumor-bearing mice (a) and after injection of~5 MBq (1 nmol) 44 Sc-DOTA/NODAGA-NOC in AR42J tumor-bearing mice (b), respectively. Data bars represent the average ± SD of values obtained from n = 3 mice well as between 44 Sc-labeled DOTA-NOC and NODAGA-NOC, respectively (Tables 2   and 3 ). When comparing variation of tumor-to-background ratios between the 44 Scand 68 Ga-labeled versions of each of the four peptides, the ratios appeared more pronounced for the NOC-based radiopeptides over their RGD-based counterparts (Tables 2  and 3) .
Preclinical PET imaging studies with Ga-labeled peptides PET/CT experiments were performed with one or two mice 3 h after injection of 44 Scand 68 respectively (Figs. 5 and 6) . 44 Sc-DOTA-RGD showed clearly less accumulation of radioactivity in the liver than 68 Ga-DOTA-RGD (Fig. 5a/b) . 44 Sc-NODAGA-RGD was comparable to 68 Ga-NODAGA-RGD but showed somewhat more background activity in the abdominal tract ( Fig. 5c/d) . The uptake pattern of 44 Sc-DOTA-RGD was slightly more favorable over the distribution of 44 Sc-NODAGA-RGD (Fig. 5a/c ).
PET/CT scans obtained at 3 h after injection of 44 Sc-DOTA-NOC revealed uptake of radioactivity only in the tumor xenografts and in the kidneys, while 68 Ga-DOTA-NOC accumulated also to a significant extent in the liver (Fig. 6a/b) . 44 Sc-NODAGA-NOC and 68 Ga-NODAGA-NOC accumulated solely in tumors and kidneys ( Fig. 6c/d ). The 44 Sc-NODAGA-NOC in the mouse, which was used for PET imaging, was reduced, resulting in lower tumor-to-kidney ratios compared to 68 Ga-NODAGA-NOC. In this context, it has to be mentioned that 44 Sc-NODAGA-NOC was prepared at a low specific activity for the PET scan ( Fig. 6c ) which implies that the injected molar amount of peptide was significantly increased compared to the peptide amount injected with 68 Ga-NODAGA-NOC and, as a result, the binding sites in the tumor tissue may have been saturated. An overview of the PET/CT scans of all four peptides labeled with 44 Sc at 5 h after injection showed largely the same tissue distribution as was found at 3 h after injection (Fig. 7) . While RGD-based peptides accumulated in the U87MG tumor xenografts and showed residual activity in the intestinal tract, NOC-based peptides accumulated in AR42J tumors xenografts and showed significant retention of radioactivity in the kidneys.
Discussion
A number of preclinical studies demonstrated the potential of 44 Sc as an alternative PET radiometal to the currently-used 68 Ga (Müller et al. 2013; Koumarianou et al. 2012; Hernandez et al. 2014; Miederer et al. 2011) . With this in mind, the possibility to extend its applications to peptides of clinical relevance is of great interest for medical physicians. Herein, we reported on the first, to our knowledge, preclinical study Sc-labeling of peptides comprising a NODAGA-chelator, as well as their in vitro and in vivo behavior. Several authors proposed the DOTA-chelator as the most suitable ligand for binding Sc(III), whereas for Ga(III) it is known that NODAGA complexes provide higher thermodynamic stability than the DOTA complex (Huclier-Markai et al. 2011; Notni et al. 2012) . Currently, the 68 Ga-DOTA functionalized somatostatin receptor analogues are among the most prominent radiopharmaceuticals for clinical PET imaging (Banerjee & Pomper 2013) . Since NODAGA derivatized biomolecules have not been used for labeling with 44 Sc to date, the question arose on whether or not sufficient stability can be achieved for in vivo application of 44 Sc-NODAGA compounds. In order to perform the preclinical experiments effectively, it was necessary to obtain the 44 Sc in a small solution volume, suitable for direct radiolabeling and subsequent in vivo application, without extensive dilution. Previously, we reported on the Sc-DOTA-RGD (a), (~10 MBq/~1 nmol) 68 Ga-DOTA-RGD (b),~10 MBq (~1 nmol) 44 Sc-NODAGA-RGD (c) and~10 MBq (~1 nmol) 68 Ga-NODAGA-RGD (d). During the PET (20 min) and the CT (1.5 min) scans the mice were anesthetized with isoflurane/oxygen (Tu = U87MG tumor xenografts, Li = liver, Int = intestines, Bl = urinary bladder)
